scholarly journals Prospective, Comparative Clinical Pilot Study of Cold Atmospheric Plasma Device in the Treatment of Atopic Dermatitis

2021 ◽  
Author(s):  
Young Jae Kim ◽  
Dong Jun Lim ◽  
Mi Young Lee ◽  
Woo Jin Lee ◽  
Sung Eun Chang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Severity Index ◽  
Skin Lesions ◽  
Treated Group ◽  
Atmospheric Plasma ◽  
Clinical Severity ◽  
Control Treatment ◽  
Cold Atmospheric Plasma ◽  
Plasma Device

Abstract Introduction: Cold atmospheric plasma generates free radicals through the ionization of air at room temperature. Its effect and safety profile in patients with atopic dermatitis have not been evaluated prospectively.Objective: We aimed to investigate the effect and safety of cold atmospheric plasma in patients with atopic dermatitis with a prospective pilot study.Methods: Cold atmospheric plasma treatment or sham control treatment were applied respectively in randomly assigned and symmetric skin lesions. Three treatment sessions were performed at weeks 0, 1, and 2. Clinical severity indices were assessed at weeks 0, 1, 2, and 4 after treatment. Additionally, the microbial characteristics of the lesions before and after treatments were analyzed.Results: We included 22 patients with mild to moderate atopic dermatitis presented with symmetric lesions. We found that cold atmospheric plasma can alleviate the clinical severity of atopic dermatitis. Modified atopic dermatitis antecubital severity and eczema area and severity index score were significantly decreased in the treated group. Furthermore, scoring of atopic dermatitis score and pruritic visual analog scales significantly improved. In microbiome analysis revealed significantly reduced proportion of Staphylococcus aureus in the treated group.Conclusion: Cold atmospheric plasma can significantly improve mild and moderate atopic dermatitis without safety issues.

scholarly journals Prospective, comparative clinical pilot study of cold atmospheric plasma device in the treatment of atopic dermatitis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Young Jae Kim ◽  
Dong Jun Lim ◽  
Mi Young Lee ◽  
Woo Jin Lee ◽  
Sung Eun Chang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Severity Index ◽  
Skin Lesions ◽  
Treated Group ◽  
Atmospheric Plasma ◽  
Clinical Severity ◽  
Control Treatment ◽  
Cold Atmospheric Plasma ◽  
Plasma Device

AbstractCold atmospheric plasma generates free radicals through the ionization of air at room temperature. Its effect and safety profile as a treatment modality for atopic dermatitis lesions have not been evaluated prospectively enough. We aimed to investigate the effect and safety of cold atmospheric plasma in patients with atopic dermatitis with a prospective pilot study. Cold atmospheric plasma treatment or sham control treatment were applied respectively in randomly assigned and symmetric skin lesions. Three treatment sessions were performed at weeks 0, 1, and 2. Clinical severity indices were assessed at weeks 0, 1, 2, and 4 after treatment. Additionally, the microbial characteristics of the lesions before and after treatments were analyzed. We included 22 patients with mild to moderate atopic dermatitis presented with symmetric lesions. We found that cold atmospheric plasma can alleviate the clinical severity of atopic dermatitis. Modified atopic dermatitis antecubital severity and eczema area and severity index score were significantly decreased in the treated group. Furthermore, scoring of atopic dermatitis score and pruritic visual analog scales significantly improved. Microbiome analysis revealed significantly reduced proportion of Staphylococcus aureus in the treated group. Cold atmospheric plasma can significantly improve mild and moderate atopic dermatitis without safety issues.

scholarly journals Treatment of atopic dermatitis using non-thermal atmospheric plasma in an animal model

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ik Jun Moon ◽  
Mi Ra Yun ◽  
Hae Kyeong Yoon ◽  
Keon Hee Lee ◽  
Sun Young Choi ◽  
...  
Keyword(s):  
Animal Model ◽  
Atopic Dermatitis ◽  
Skin Barrier ◽  
Treated Group ◽  
Transepidermal Water Loss ◽  
Atmospheric Plasma ◽  
Therapeutic Modality ◽  
Skin Barrier Function ◽  
Control Group ◽  
Epidermal Thickness

AbstractCold atmospheric plasma (CAP) has been incorporated into various fields, including promotion of cutaneous wound healing. Atopic dermatitis (AD) is a chronic cutaneous condition characterized by inflammation-induced skin wounds and impaired skin barrier function. To investigate whether CAP may improve AD using an animal model. Dermatophagoides farinae extracts (DFE)-induced murine models of AD were used in this study. The plasma-treated group received a total of 6 CAP treatments during 2 weeks, while the control group did not receive any treatment. Differences in dermatitis severity, transepidermal water loss (TEWL), serum level of immunoglobulin (Ig) E and epidermal thickness were evaluated in both groups. The dermatitis severity was significantly improved by CAP treatment. TEWL was lower in the plasma-treated group compared with the non-treated control group. Serum Ig E dropped significantly after treatment with CAP. Difference in epidermal thickness of the ear skin was not significant between the plasma-treated and non-treated groups. Localized treatment of AD with CAP decreases dermatitis severity, TEWL, and serum Ig E level. These results show CAP’s potentials as a novel therapeutic modality for AD.

scholarly journals The Use of Cold Atmospheric Plasma Device in Flap Elevation

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Massimo Pinelli ◽  
Marta Starnoni ◽  
Giorgio De Santis
Keyword(s):  
Atmospheric Plasma ◽  
Cold Atmospheric Plasma ◽  
Plasma Device ◽  
Flap Elevation

scholarly journals Inhibitory Effect ofNelumbo nucifera(Gaertn.) on the Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Rajendra Karki ◽  
Myung-A Jung ◽  
Keuk-Jun Kim ◽  
Dong-Wook Kim
Keyword(s):  
Atopic Dermatitis ◽  
Severity Score ◽  
Histopathological Examination ◽  
Skin Lesions ◽  
Transepidermal Water Loss ◽  
Inhibitory Effect ◽  
Clinical Severity ◽  
Inflammatory Skin Disease ◽  
Level Measurement ◽  
Different Doses

Atopic dermatitis (AD) is a chronic inflammatory skin disease which has a complex etiology that encompasses immunologic responses. The study was carried out to examine the effect ofNelumbo nucifera(Gaertn.) leaf (NL) on the AD-like skin lesion induced by repeated epicutaneous application of 2,4-dinitrochlorobenzene (DNCB) on the dorsal skin of NC/Nga mice. Three different doses of NL (5, 25, and 50 mg/mice/day) were administered orally from the day of sensitization with DNCB for 4 weeks. The efficacy of NL was judged by histopathological examination, blood IgE level, measurement of transepidermal water loss (TEWL), scratching behavior, and skin severity score. NL resulted in the suppression of clinical severity score, TEWL, scratching behavior, and blood IgE level. Histopathologic analyses revealed that thickening of the epidermis and mast cell degranulation was significantly reduced in NL group. These results suggest that NL may be a useful natural resource for the management of AD.

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

2010 ◽  
Vol 13 (4) ◽  
pp. 681-688 ◽  
Author(s):  
I. Taszkun
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Clinical State ◽  
Point Scale ◽  
Canine Atopic Dermatitis ◽  
Group I ◽  
Oral Preparation ◽  
Sandimmun Neoral ◽  
Anti Inflammatory

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone The purpose of this study was to assess the clinical state of dogs with atopic dermatitis (AD) by use of CADESI test in own modification during the first visit in the Dermatology Consult Room as well as during the treatment. The study was performed in two groups (I-E and II-C) of 20 dogs in each group. In dogs which were qualified to the I-E group, as antiallergic, anti-inflammatory and antipruritic treatment, prednisone (oral preparation Encorton - Polfa Pabianice) at dose 0.5 mg/kg b.w./day was administered, while in dogs qualified to the II-C group - cyclosporine (oral preparation Sandimmun Neoral - Novartis Pharma) at a dose of 5 mg/kg b.w./day; the treatment was continued for 6 weeks in both groups. During the study, skin lesions were assessed in 15 specified body areas using 4 parameters and 5-point scale. In group I-E and II-C the amount of received points in CADESI test was decreased by 82.26% and by 83% respectively, after the treatment. Statistical analyses of the results obtained revealed no statistically significant (P=0.05) differences between means of I-E and II-C groups in consecutive examinations, which indicates comparable clinical efficacy of both drugs. Statistically significant differences (P=0.05) of the parameters assessed were found after secondary dermatoses treatment, and after every two weeks of antipruritic and anti-inflammatory treatment.

scholarly journals Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment

2021 ◽  
Vol 7 (36) ◽  
Author(s):  
Guojun Chen ◽  
Zhitong Chen ◽  
Zejun Wang ◽  
Richard Obenchain ◽  
Di Wen ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Atmospheric Plasma ◽  
Cold Atmospheric Plasma ◽  
Plasma Device

Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs

2014 ◽  
Vol 25 (2) ◽  
pp. 77-e25 ◽  
Author(s):  
Thierry Olivry ◽  
Manolis Saridomichelakis ◽  
Tim Nuttall ◽  
Emmanuel Bensignor ◽  
Craig E. Griffin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Severity Scale ◽  
Canine Atopic Dermatitis

scholarly journals Melanoma Growth Analysis in Blood Serum and Tissue Using Xenograft Model with Response to Cold Atmospheric Plasma Activated Medium

2019 ◽  
Vol 9 (20) ◽  
pp. 4227 ◽  
Author(s):  
Manish Adhikari ◽  
Bhawana Adhikari ◽  
Neha Kaushik ◽  
Su-Jae Lee ◽  
Nagendra Kumar Kaushik ◽  
...  
Keyword(s):  
Blood Serum ◽  
Xenograft Model ◽  
Treated Group ◽  
Tissue Level ◽  
Atmospheric Plasma ◽  
Cold Atmospheric Plasma ◽  
Melanoma Cancer ◽  
Mda Content ◽  
Apoptotic Genes

Background: Cold atmospheric plasma (CAP) proposed as a novel therapeutic tool for the various kinds of cancer treatment. Cold atmospheric Plasma-Activated Media (PAM) has exhibited its promising application in plasma medicine for the treatment of cancer. Methods: We investigated the role of PAM on the human melanoma cancer G-361 cells xenograft in vivo by estimating the biochemical and gene expression of apoptotic genes. Results: Reactive oxygen and nitrogen species (RONS) generated by PAM could significantly decrease the tumor volume (40%) and tumor weight (26%) when administered intradermally (i.d.) into the melanoma region continuously for three days. Biochemical studies in blood serum along with excised melanoma samples revealed an increase in protein carbonylation and MDA content as compared to the control, while LDH and L-DOPA in serum and melanoma tissues were decreased significantly in PAM treated group. PAM generated RONS increased apoptotic genes like Bcl-2, Bax, Parp, Casp8, and P53 in melanoma tissue. Immunohistochemistry data confirms that PAM treatment increased apoptosis at the tissue level. Conclusions: These results suggested that RONS present in PAM inhibit the induction of xenograft melanoma cancer cells through the induction of apoptosis and upregulating of various biochemical parameters within blood serum and melanoma.

Sign in / Sign up

Export Citation Format

Share Document